PBGH in the News


January 10, 2021

Amazon, JPMorgan Chase, Berkshire Hathaway disband Haven

The Pacific Business Group on Health created a narrow network of high-quality providers that its member employers contract with directly […]

January 5, 2021

Health Lobbyist Spent $75 Million to Kill Surprise Medical Bills Reform

“A health lobby group reportedly spent tens of millions of dollars in a campaign to influence legislation aimed at ending […]

December 30, 2020

PBGH CEO discusses the landmark Sutter Health lawsuit on 60 Minutes

Hospital consolidation is one of the main reasons the cost of health care in this country is going through the roof.

December 23, 2020

With Freezers in Tow, U.S. Employers Rush to Fill Vaccine Void

Most employers say they’ll strongly encourage the COVID-19 vaccines but not require them.

December 23, 2020

Planning for COVID Vaccines and Costs

COVID-19 drugs and therapeutics were developed with significant federal investment; that should be reflected in their pricing.

December 23, 2020

3 Reasons Employers Should Be Concerned About ACA Repeal

Employers have concerns surrounding the legal challenge to the Affordable Care Act (ACA).

December 23, 2020

PBGH issues statement on Xavier Becerra HHS nomination

On December 7, 2020, the Pacific Business Group on Health (PBGH) issued this statement  regarding the announcement that President-elect Biden will nominate California Attorney General Xavier Becerra to serve as Secretary of the U.S. Department of Health and Human Services (HHS).

December 23, 2020

New Trump administration rule directs insurers to reveal what they pay for prescriptions

“There’s a limit to what transparency can do,” said Shawn Gremminger, health policy director at the Pacific Business Group on Health, which represents large self-insured employers. “That’s why we’re increasingly comfortable with policies that get at the underlying prices of drugs.” As an example, he cited the Trump administration’s proposal to tie what Medicare pays for drugs to lower prices in other countries.

December 23, 2020

US needs price controls for COVID-19 drugs, employer advocacy group says

The Employers’ Prescription for Affordable Drugs said Medicare should determine fair prices for COVID-19 drugs and vaccines and pointed to Gilead’s remdesivir as an example of an overpriced drug. The FDA approved remdesivir as a COVID-19 treatment in October. The drug costs private health plans more than $3,00 per treatment course, Bloomberg reported.

December 23, 2020

Private employers show new interest in expanded Medicare and regulated drug prices

“There is a significant difference in what employers are prepared to support,” said Elizabeth Mitchell, president of the Pacific Business Group on Health, a consortium of large companies including Boeing, Safeway, Walmart and Wells Fargo.